CNS Drugs https://doi.org/10.1007/s40263-018-0531-7 CORRECTION Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents 1 1 Michael W. Jann Scott R. Penzak Springer International Publishing AG, part of Springer Nature 2018 Correction to: CNS Drugs (2018) 32 (3): 241–257 experienced acute exacerbations and in patients who https://doi.org/10.1007/s40263-018-0508-6 required maintenance treatment [21, 45, 46]. 3. On Page 246, under Paliperidone Palmitate, column 2— 1. On Page 244, under General Pharmacokinetic Principles, the text that read: Column 1—the following sentence should come after ref- The pharmacokinetics of 3MPP were characterized in a erence 21: single-dose study in which patients received doses ranging ‘‘Doses of intramuscular paliperidone palmitate can be from 75 to 525 mg (819 mg) . conveyed in mg of paliperidone palmitate or as mg Should read as: equivalents of paliperidone (active moiety, mg eq). For example, 156 mg of intramuscular paliperidone palmitate The pharmacokinetics of 3MPP were characterized in a is equivalent to 100 mg of paliperidone per mL of aqueous single-dose study in which patients received doses ranging suspension [11, 21]. In this article, we present doses of from 75 to 525 mg . intramuscular paliperidone palmitate in mg, i.e. ‘75 mg’ 4. On Page 246, under Paliperidone Palmitate, column 2— refers to 75 mg eq of paliperidone, which is equivalent to the text that read: 117 mg of paliperidone palmitate.’’ In a randomized multicenter clinical trial, 506 patients with 2. On Page 246, under Paliperidone Palmitate column 2— schizophrenia received 3MPP in four phases: (1) screening, the text that read: (2) 1MPP treatment for 17 weeks, (3) 3MPP single-dose The efﬁcacy and safety of 1MPP has been established in administration, and (4) double-blind randomization of patients with schizophrenia who experience acute exacerba- drug-versus-placebo (1:1) . tions and in patients requiring maintenance treatment [45, 46]. Should read as: Should read as: In a randomized, multicentre, multi-phase clinical trial, patients The efﬁcacy and safety of 1MPP was established for reg- with schizophrenia received 1MPP treatment for 17 weeks ulatory approval in patients with schizophrenia who (n = 506) followed by a single dose of 3MPP (n = 379) and then entered a double-blind randomization drug-versus-pla- cebo phase (n = 160 vs 145, respectively) . The original article can be found online at https://doi.org/10.1007/ s40263-018-0508-6. 5. On Page 246, under Paliperidone Palmitate, column 2—reference to Table 2 should be removed from the text & Michael W. Jann Michael.firstname.lastname@example.org that reads: A dosing conversion factor of 3.5 was used when switching Department of Pharmacotherapy, University of North Texas System College of Pharmacy (UNTSCP), University of North patients from 1MPP to 3MPP based on 1MPP and 3MPP Texas Health Science Center (UNTHSC), 3500 Camp Bowie pharmacokinetic proﬁles. Blvd., Fort Worth, TX 76107, USA
CNS Drugs – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera